- Home
- TLK vs UTHR Comparison
TLK vs UTHR Comparison
Compare TLK & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLK
- UTHR
- Stock Information
- Founded
- TLK 1884
- UTHR 1996
- Country
- TLK Indonesia
- UTHR United States
- Employees
- TLK N/A
- UTHR N/A
- Industry
- TLK Telecommunications Equipment
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- TLK Telecommunications
- UTHR Health Care
- Exchange
- TLK Nasdaq
- UTHR Nasdaq
- Market Cap
- TLK 16.2B
- UTHR 16.1B
- IPO Year
- TLK 1995
- UTHR 1999
- Fundamental
- Price
- TLK $15.95
- UTHR $361.10
- Analyst Decision
- TLK
- UTHR Buy
- Analyst Count
- TLK 0
- UTHR 13
- Target Price
- TLK N/A
- UTHR $382.08
- AVG Volume (30 Days)
- TLK 703.7K
- UTHR 377.3K
- Earning Date
- TLK 03-21-2025
- UTHR 02-26-2025
- Dividend Yield
- TLK 6.95%
- UTHR N/A
- EPS Growth
- TLK N/A
- UTHR 25.10
- EPS
- TLK 0.02
- UTHR 22.72
- Revenue
- TLK $9,920,511,850.00
- UTHR $2,756,200,000.00
- Revenue This Year
- TLK $3.31
- UTHR $26.10
- Revenue Next Year
- TLK $3.20
- UTHR $10.43
- P/E Ratio
- TLK $10.79
- UTHR $16.00
- Revenue Growth
- TLK 0.35
- UTHR 25.04
- 52 Week Low
- TLK $14.16
- UTHR $218.41
- 52 Week High
- TLK $26.41
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- TLK 49.23
- UTHR 48.08
- Support Level
- TLK $15.95
- UTHR $364.62
- Resistance Level
- TLK $16.29
- UTHR $383.51
- Average True Range (ATR)
- TLK 0.33
- UTHR 11.17
- MACD
- TLK 0.08
- UTHR 1.30
- Stochastic Oscillator
- TLK 74.69
- UTHR 42.76
About TLK PT Telekomunikasi Indonesia Tbk
PT Telkom Indonesia (Persero) Tbk is the integrated telecommunications provider in Indonesia. The company is focusing on dividing business into 3 Digital Business Domains namely, digital connectivity, digital platform, and digital services. It also provides a wide range of other communication services, including telephone network, interconnection services, multimedia, data and internet communication-related services, satellite transponder leasing, leased line, intelligent network and related services, cable television, and VoIP services.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.